Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease.
Background: Previous studies indicate a role of P2X7 receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X7 receptors influenced dopaminergic cell death in various models of Parkinson's disease (PD). Results: mRNA encoding P2X7 and P2X4 receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7 antagonists protected against MPTP and rotenone induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7 receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X4 receptors was higher in P2X7 knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7 receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7 knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7 deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7 receptors. Conclusions: We conclude that P2X7 receptor deficiency or inhibition does not support the survival of dopaminergic neurons in an in vivo or in vitro models of PD.
Neurons, the cells in the brain communicate chemically with each other by releasing small amounts of chemicals. The composition of the signaling molecules that they release in response to various stimuli is a complex cocktail of neurotransmitters. We developed a sensitive analytical method to investigate how the concentration of signaling molecules changes under the pathologically relevant conditions. The major modifications incorporated into this method include: the reaction of dansyl amide and dansylsulphoarachidonic ester were accelerated by high pH value; modification of the gradient profile to elute amino acids, monoamines and common endocannabinoids within the same run; addition of steps for sample enrichment and cleaning the excess of dansylchloride within each run; shorter re-equilibration time. The quantitative analysis study in rat striatum revealed the interval of extra cellular levels of amino acids, monoamines and endocannabinoids between 0.5 and 250 nM. Upon rotenone treatment, an in vitro model of Parkinson’s disease (PD), the electric field stimulation increased the concentrations of dopamine (DA), glutamate (Glu), serotonin (5-HT) and 2-arachidonylglycerol (2-AG) in the slice perfusate. When, peroxide stimulation was applied in association rotenone treatment with D2 type dopamine receptor agonist, bromocriptine revealed increases of DA, 5-HT and 2-AG, while the Glu, GABA and anandamide (AEA) no alterations in basal levels in slice perfusate. In line with above line of D2 agonist, ropinirole elevated the concentrations of DA, noradrenalin (NA), 5-HT and Glu. In conclusion, the development of this method allows the direct, temporal analysis of co-released neurotransmitters in tissue over flow-fluid and increases our understanding of changes with neurodegenerative diseases.